Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bochum
Clinical trial register · Germany

Clinical Trials in Bochum, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5042 matching records held by the registry are in this view. Synced 02 Oct 2026, 03:17 UTC
5042
Studies in scope
all four open statuses
2868
Recruiting now
open to new participants
984
Lead sponsors
across recruiting studies
Top sites
Berlin 1586 Hamburg 888 Essen 763 Dresden 709 Heidelberg 626
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca16 Novartis Pharmaceuticals11 Hoffmann-La Roche8 Novo Nordisk A/S7 argenx6
Site location
Berlin1586 Hamburg888 Essen763 Dresden709 Heidelberg626
All 637 locations
Target enrolment
to

Trials with a site in Bochum

203 of 5042 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
Bochum, Essen, München, Münster
2026-10-15
Not yet open
Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform
NCT07825233Rheumatoid Arthritis (RA
Centre Hospitalier Universitaire Vaudois
Not applicable
142
Berlin, Bochum
2026-09-28
Not yet open
Flow-Controlled Ventilation to Improve Postoperative Pulmonary Outcome After Thoracic Surgery
NCT07623395Mechanical Ventilation, Postoperative Pulmonary Complications (PPCs)
Cantonal Hospital of St. Gallen
Not applicable
140
Bochum
2026-09-01
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Berlin, Bochum, Hanover, Hohenmölsen, Karlsruhe, Leipzig, Obertshausen, Offenbach
2026-08-26
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Cologne
2026-08-24
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca
Phase 3
1,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugLenbelintide
AstraZeneca
Phase 3
2,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-19
Recruiting
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
NCT05314998Pancreatic Ductal Adenocarcinoma
DrugsFolinic acid·Irinotecan·Adrucil·Capecitabine
John Neoptolemos
Phase 3
394
Aachen, Augsburg, Bochum, Bonn, Deggendorf, Dresden, Erlangen, Frankfurt
2026-08-17
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131Hypercholesterolaemia
DrugsRosuvastatin 1·Rosuvastatin 2
AstraZeneca
Phase 3
600
Ahrensburg, Berlin, Bochum, Gladbeck, Hamburg, Hanover, Karlsruhe, Leipzig
2026-08-12
Recruiting
NG004 in Incomplete Spinal Cord Injury Patients
NCT07840196Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Spinal Cord Injuries, Trauma Nervous System
DrugNG004
NovaGo Therapeutics AG
Phase 1
120
Bayreuth, Bochum, Halle, Hamburg, Heidelberg, Murnau am Staffelsee, Tübingen
2026-08-05
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsEnfortumab Vedotin·Rilvegostomig·Dato-DXd·Opdivo
AstraZeneca
Phase 3
915
Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Hamburg, Hanover, Herne
2026-07-16
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
NCT07664553Type 2 Diabetes Mellitus
DrugElecoglipron
AstraZeneca
Phase 3
600
Amberg, Bad Oeynhausen, Berlin, Bochum, Brandenburg an der Havel, Daaden, Duisburg, Eisenach
2026-07-08
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Aachen, Bochum, Erlangen, Münster, Taufkirchen, Ulm
2026-07-01
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
NCT07668388Diabetes Mellitus, Type 2
DrugsUBT251·Semaglutide
Novo Nordisk A/S
Phase 2
300
Amberg, Bad Oeynhausen, Berlin, Bochum, Bünde, Essen, Hof, Mannheim
2026-06-22
Recruiting
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
NCT07633158Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca
Observational
200
Bochum, Braunschweig, Dortmund, Dresden, Hagen, Hamburg, Heilbronn, Jena
2026-06-10
Recruiting
Refocus VisAbility™ Micro Insert System Pre-market Clinical Trial
NCT07637500Presbyopia
VisDura, Inc.
Not applicable
33
Bochum, Heidelberg
2026-06-02
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
DrugsImlunestrant·Goserelin·Tamoxifen
Eli Lilly and Company
Phase 2
600
Bergisch Gladbach, Berlin, Bielefeld, Bochum, Bonn, Bottrop, Braunschweig, Bremen
2026-05-13
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Aachen, Bad Friedrichshall, Bad Oeynhausen, Berlin, Bochum, Coburg, Cologne, Dresden
2026-05-11
Recruiting
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Bochum, Hamburg, Hanover, Karlsruhe, Münster, Schleswig
2026-05-05
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Bochum, Hamburg, Hanover, Karlsruhe, Münster, Schleswig
2026-05-05
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene
Merck Sharp & Dohme LLC
Phase 3
876
Heidelberg, Bochum
2026-05-04
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Berlin, Bochum, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2026-04-09
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 3
770
Aachen, Bochum, Münster, Tübingen, Ulm
2026-03-24
Recruiting
Mental Health and Suicidality in Glioblastoma Patients in Germany
NCT07409584Glioblastoma (GBM)
University Hospital, Essen
Observational
180
Berlin, Bochum, Essen, Hamburg, Heidelberg, Münster
2026-03-18
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Freiburg im Breisgau, Mannheim, Tübingen, Ulm, Erlangen, Munich, Bochum, Düsseldorf
2026-03-10
Recruiting
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07221838Generalized Myasthenia Gravis, gMG
DrugsPrednisone/Prednisolone·Ravulizumab
Alexion Pharmaceuticals, Inc.
Phase 4
75
Bochum
2026-03-04
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814Acute Myeloid Leukemia
DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
875
Aachen, Bochum, Bonn, Greifswald, Halle, Hanover, Heilbronn, Karlsruhe
2026-03-01
Not yet open
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
NCT07417683Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH
Trans-Duodenal Concepts GmbH
Not applicable
126
Mannheim, Bamberg, Würzburg, Bochum, Dresden, Leipzig, Berlin
2026-03
Recruiting
In Vivo Exposure vs. Videochat-Based Vicarious Exposure
NCT07432945Anxiety, Anxiety Disorders
Ruhr University of Bochum
Not applicable
72
Bochum
2026-02-26
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Bochum, Bünde, Duisburg, Hamburg, Karlsruhe, Leipzig, München, Offenbach
2026-02-09
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263Hidradenitis Suppurativa
DrugZasocitinib
Takeda
Phase 2
90
Bad Bentheim, Bochum, Mainz, Berlin
2026-01-26
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975Hidradenitis Suppurativa (HS)
Navigator Medicines, Inc.
Phase 2
150
Bochum, Frankfurt, Kiel, Lübeck, Mainz
2026-01-05
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Erlangen, Hanover, Dresden, Berlin, Bochum, Chemnitz, Düsseldorf, Frankfurt
2025-12-31
Recruiting
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese
NCT07326111Polycystic Ovary Syndrome (PCOS), Obesity & Overweight
University of Bonn
Phase 4
198
Bochum, Bonn
2025-12-09
Recruiting
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
NCT07255638Indolent Systemic Mastocytosis
DrugAvapritinib
Blueprint Medicines Corporation
Observational
80
Berlin, Bochum, Deggendorf, Dresden, Göttingen, Tübingen, Wiesbaden, Wuppertal
2025-12-09
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg
2025-12-03
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Beelitz, Berlin, Bochum, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hanover
2025-11-24
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842Advanced Solid Cancers
BioNTech SE
Phase 1/2
245
Bochum, München, Ulm
2025-11-18
Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420Palmoplantar Pustulosis
DrugBimekizumab
UCB Biopharma SRL
Phase 3
320
Ahaus, Bad Bentheim, Berlin, Bielefeld, Bochum, Dresden, Göttingen, Kiel
2025-11-14
Active, closed
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886Multiple Sclerosis
Hoffmann-La Roche
Phase 2
193
Berlin, Bochum, Dresden, Tübingen
2025-11-13
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
DrugBrivekimig
Sanofi
Phase 2
208
Bochum, Bramsche, Frankfurt, Kiel, Mainz, Münster, Würzburg
2025-11-06
Active, closed
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Bochum, Frankfurt, Heidelberg, Leipzig, Lübeck, Munich
2025-11-03
Recruiting
A Study With CIT-013 in HS Patients
NCT06993233Hidradenitis Suppurativa (HS)
DrugsCIT-013 medium·CIT-013
Citryll BV
Phase 2
96
Bad Bentheim, Bochum, Dresden, Frankfurt, Kiel, Oldenburg
2025-10-31
Recruiting
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
NCT06856837Metastatic Colorectal Cancer
DrugsLonsurf·Trifluridine/Tipiracil·Fruquintinib·Avastin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
140
Amberg, Bad Saarow, Berlin, Bochum, Düsseldorf, Essen, Frankfurt, Frankfurt am Main
2025-10-27
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
By invitation
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
NCT07032246Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome
icometrix
Not applicable
750
Bochum, Dresden, Berlin
2025-10-09
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NCT07210463Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz Aesthetics GmbH
Phase 3
300
Munich, Blankenfelde-Mahlow, Potsdam, Friedrichsdorf, Kassel, Bochum, Düsseldorf, Drensteinfurt
2025-10-01
Active, closed
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,101
Aachen, Bad Homburg, Bayreuth, Bochum, Bremen, Erbach/Odenwald, Freiburg im Breisgau, Hamburg
2025-09-17
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Bochum, Dresden, Hamburg, Hanover, Karlsruhe, Leipzig, München, Offenbach
2025-09-15
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Bochum, Bonn, Cologne, Dortmund, Karlsruhe, Lübeck, Stuttgart, Ulm
2025-09-04
Not yet open
5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab
NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2
300
Bochum, Frankfurt, Göttingen, Hamburg
2025-08-31
Recruiting
SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
NCT07145190Parkinson Disease
Bial - Portela C S.A.
Observational
90
Berlin, Bochum, Freiburg im Breisgau, Fulda, Hetzdorf, Osnabrück, Siegen, Sundern
2025-08-27
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin aspart·Insulin glargine·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Bad Mergentheim, Bad Oeynhausen, Berlin, Bochum, Dresden, Eisenach, Essen, Gelnhausen
2025-08-11
Recruiting
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
NCT07075016Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Flensburg, Freiburg im Breisgau
2025-08-05
Recruiting
PROtective Ventilation With FLOW-Controlled Ventilation
NCT06703814Postoperative Pulmonary Complications (PPCs), Feasibility Studies, Pilot Study
Cantonal Hospital of St. Gallen
Not applicable
100
Bochum
2025-08-02
Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
NCT07047703Axial Spondyloarthritis (AxSpA)
Grey Wolf Therapeutics
Phase 1/2
140
Bochum, Erlangen
2025-07-28
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
12,800
Bad Homburg, Bad Krozingen, Bad Oeynhausen, Berlin, Bochum, Bonn, Detmold, Dortmund
2025-07-25
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,800
Bad Homburg, Bad Krozingen, Bad Oeynhausen, Berlin, Bochum, Bremen, Bruchsal, Coburg
2025-07-22
Not yet open
Biphasic Positive Airway Pressure Ventilation Versus Flow-Controlled Ventilation in Burn Patients
NCT07041957Burn Injury, Inhalational Injury, Pulmonary Complications, Ventilator-induced Lung Injury (VILI)
University Hospital Bergmannsheil Bochum
Not applicable
24
Bochum
2025-07
By invitation
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637Hidradenitis Suppurativa
DrugSonelokimab
MoonLake Immunotherapeutics AG
Phase 3
835
Halle, Augsburg, Bad Bentheim, Berlin, Bielefeld, Bochum, Bramsche, Darmstadt
2025-06-27
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Berlin, Bochum, Erbach im Odenwald, Essen, Greifswald, Heidelberg, Münster, Ulm
2025-06-23
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
580
Berlin, Bochum, Darmstadt, Dresden, Erlangen, Hamburg, Lübeck
2025-06-23
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034Gastrointestinal Neoplasms
DrugRisvutatug rezetecan
GlaxoSmithKline
Phase 1/2
451
Bochum, Düsseldorf, Frankfurt, Lübeck, München
2025-06-11
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 3
1,755
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2025-06-09
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Würzburg, Kassel, Bochum, Münster, Siegen, Meisenheim, Jena, Bielefeld
2025-06-05
Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627Venous Leg Ulcer (VLU)
DrugEscharEx
MediWound Ltd
Phase 3
216
München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel
2025-06-01
Recruiting
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916Generalized Myasthenia Gravis
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 3
231
Bochum, Goettigen, Magdeburg, Würzburg
2025-05-27
Active, closed
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610Hidradenitis Suppurativa (HS)
Zura Bio Inc
Phase 2
225
Bad Bentheim, Bochum, Darmstadt, Dresden, Hamburg, Heidelberg, München, Münster
2025-05-16
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438Acute Myeloid Leukemia, Adult
DrugRevumenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Essen, Flensburg
2025-05-05
Recruiting
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
NCT06538064Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Observational
30
Rüdersdorf, Marburg, Bochum, Berlin
2025-04-29
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
Bad Mergentheim, Bochum, Essen, Hamburg, Karlsburg, Leipzig, Münster, Oldenburg
2025-04-25
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Recruiting
Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
NCT06867705Cancer
Resilience
Phase 3
1,458
Augsburg, Bad Saarow, Bochum, Hamburg, Hanover, Hösbach, Kiel, Lübeck
2025-04-01
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Berlin, Bochum, Essen, Tübingen, Ulm, Würzburg
2025-03-18
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
11,300
Aachen, Amberg, Bad Homburg, Bad Oeynhausen, Bamberg, Bechhofen, Berlin, Bochum
2025-03-14
Recruiting
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
NCT06571149Ischemic Stroke
DrugsAlteplase·Tenecteplase
Insel Gruppe AG, University Hospital Bern
Phase 4
906
Karlsbad, Bad Neustadt an der Saale, Bamberg, Bochum, Bottrop, Erfurt, Essen, Frankfurt
2025-03-14
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
5,000
Bad Homburg, Bamberg, Berlin, Bochum, Brandenburg an der Havel, Dresden, Essen, Friedrichsthal
2025-03-03
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
600
Aachen, Bad Bentheim, Berlin, Bochum, Bonn, Buxtehude, Darmstadt, Dortmund
2025-02-28
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT06764706Ulcerative Colitis
AbbVie
Observational
200
Heidelberg, Potsdam, Tostedt, Hanover, Schwerin, Ahaus, Bochum, Cologne
2025-02-27
Active, closed
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793Relapsing Multiple Sclerosis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
28
Bochum, Essen, Mainz, Ulm
2025-02-24
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
56
Tübingen, Erlangen, Oldenburg, Bochum
2025-02-19
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
588
Langenau, Darmstadt, Dresden, Halle, Berlin, Bochum, Bonn, Erlangen
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Frankfurt am Main, Bochum, Mainz, Dresden, Leipzig, Berlin
2025-01-29
Active, closed
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma
DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine
Arcus Biosciences, Inc.
Phase 3
610
Bochum, Frankfurt am Main, Hamburg, Hanover, Heilbronn, Magdeburg, Riesa, Ulm
2024-12-13
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt
2024-11-27
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
Munich, Bochum, Hamburg, Tübingen
2024-11-25
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Bad Berka, Berlin, Bielefeld, Bochum, Chemnitz, Cologne, Essen, Esslingen am Neckar
2024-11-18
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Berlin, Bochum, Cologne, Dresden, Frankfurt, Heidelberg, Homburg, Landshut
2024-11-12
Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
NCT06298565Myasthenia Gravis
DrugEfgartigimod
argenx
Observational
680
Altenburg, Bochum, Göppingen, Göttingen, Gummersbach, Jena, Würzburg
2024-11-04
Active, closed
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
NCT05888922Androgenetic Alopecia, Female Pattern Baldness
DrugMinoxidil
Industrial Farmacéutica Cantabria, S.A.
Phase 3
520
Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau
2024-10-17
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt, Heidelberg, Homburg
2024-10-14
Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449Huntington's Disease
Alnylam Pharmaceuticals
Phase 1
66
Berlin, Bochum, Bonn, Dresden, Münster, Taufkirchen, Ulm
2024-10-14
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698Liver Diseases, Alcoholic
DrugGSK4532990
GlaxoSmithKline
Phase 2
393
Bochum, Berlin, Kiel, Leipzig, Mainz
2024-09-27
Active, closed
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
151
Freiburg im Breisgau, Ulm, Munich, Regensburg, Würzburg, Giessen, Buxtehude, Bochum
2024-09-18
Active, closed
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 4
500
Bochum, Göttingen, Hanover, Leipzig, Ulm
2024-09-17
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis
DrugsKYV-101·Fludarabine·Cyclophosphamide
Kyverna Therapeutics
Phase 2/3
66
Berlin, Bochum, Hamburg, Hanover, Jena, Magdeburg, Munich
2024-08-28
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
Berlin, Bochum, Bremen, Essen, Göttingen, Hanover, Homburg, Münster
2024-08-21
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Munich, Regensburg, Würzburg, Frankfurt am Main, Bochum, Essen
2024-07-31
Recruiting
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias
NCT07798674Hereditary Spastic Paraplegia, Spastic Ataxia
Heidelberg University
Observational
4,000
Bochum, Bonn, Dresden, Erlangen, Essen, Göttingen, Heidelberg, Kiel
2024-07-16
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Bad Homburg, Berlin, Bochum, Essen, Giessen, Tübingen
2024-07-12
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Berlin, Bochum, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hanover, Kiel
2024-06-29
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Freiburg im Breisgau, Tübingen, Erlangen, Memmingen, Darmstadt, Bad Bentheim, Rostock, Bochum
2024-06-27
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Ulm, Göttingen, Hanover, Bochum, Düsseldorf, Dresden, Leipzig, Lübeck
2024-06-25
Recruiting
Ultra-high-caloric, Fatty Diet in ALS
NCT06280079Amyotrophic Lateral Sclerosis
University of Ulm
Not applicable
392
Aachen, Berlin, Bochum, Bonn, Dresden, Erlangen, Essen, Göttingen
2024-06-01
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bayreuth, Berlin, Bochum, Dresden, Düsseldorf, Essen, Giessen, Hamburg
2024-04-16
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
DrugEfgartigimod
argenx
Phase 3
119
Berlin, Bochum, Würzburg
2024-04-16
Active, closed
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750Prurigo Nodularis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
140
Augsburg, Bad Bentheim, Berlin, Bochum, Erlangen, Frankfurt, Heidelberg, Münster
2024-04-12
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 3
2,554
Aachen, Amberg, Bad Oeynhausen, Berlin, Bochum, Dresden, Essen, Falkensee
2024-03-29
Recruiting
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119First Progression of Glioblastoma
DrugLomustine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Bochum, Cologne, Erlangen, Essen, Heidelberg, Leipzig, Munich, Regensburg
2024-03-15
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
731
Augsburg, Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Dülmen, Düsseldorf
2024-03-09
Recruiting
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
NCT06280755Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
icometrix
Observational
7,000
Bochum, Berlin
2024-03-01
Recruiting
A Global Prospective Observational Registry of Patients With Pompe Disease
NCT06121011Pompe Disease
DrugsAlglucosidase alfa·Cipaglucosidase alfa·Miglustat·Avalglucosidase alfa
Amicus Therapeutics
Observational
500
Bochum, Höchheim, Marburg, München, Ulm
2024-02-16
Recruiting
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
NCT06078553Congenital Myasthenic Syndrome
argenx
Observational
100
Berlin, Bochum, Essen
2024-02-13
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999Hidradenitis Suppurativa (HS)
DrugPovorcitinib
Incyte Corporation
Phase 3
617
Berlin, Bochum, Darmstadt, Dessau, Dresden, Düsseldorf, Erlangen, Frankfurt
2024-01-30
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Bielefeld, Bochum, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Heidelberg, Jena
2023-12-27
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Bielefeld, Bochum, Böblingen, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Giessen
2023-12-13
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Esslingen am Neckar, Gauting, Kempten (Allgäu), Regensburg, Bochum, Münster, Paderborn, Großhansdorf
2023-12-06
Recruiting
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
NCT06246136Open Angle Glaucoma
Elios Vision, Inc.
Not applicable
194
Bochum, Bonn, Heidelberg
2023-12-05
Recruiting
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
NCT06299748Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugEfgartigimod
argenx
Observational
279
Bochum
2023-11-30
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Yervoy·Paraplatin·Opdivo
AstraZeneca
Phase 3
863
Berlin, Bochum, Cologne, Essen, Gauting, Georgsmarienhütte, Großhansdorf, Hamburg
2023-11-09
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Darmstadt, Bielefeld, Bochum, Bonn, Mainz, Dresden, Leipzig, Magdeburg
2023-11-08
Recruiting
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
NCT05658497Multiple Sclerosis
DrugsDiroximel Fumarate·Natalizumab·Avonex·Dimethyl Fumarate
Biogen
Observational
908
Bochum
2023-10-27
Recruiting
Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI
NCT05786131Non-ST-elevation Myocardial Infarction, Multivessel Coronary Artery Disease
Leipzig Heart Science gGmbH
Not applicable
3,390
Bad Berka, Bad Krozingen, Bad Nauheim, Bad Oeynhausen, Berlin, Bielefeld, Bochum, Bremen
2023-10-27
Recruiting
GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications
NCT05867927GYN Disorders
Intuitive Surgical
Observational
1,250
Hamburg, Wiesbaden, Berlin, Bochum, Coburg, Cologne, Essen, Frankfurt am Main
2023-10-25
Active, closed
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326Adenocarcinoma, Pancreatic Ductal
DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab
Genentech, Inc.
Phase 2
260
Berlin, Bochum, Cologne, Dresden, Essen, Frankfurt, Hamburg, Heidelberg
2023-10-18
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
NCT06095102Plaque Psoriasis
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
311
Berlin, Bochum, Darmstadt, Dresden, Frankfurt am Main, Hamburg, Schwerin, Witten
2023-10-12
Recruiting
The ReTAVI Prospective Observational Registry
NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction
Institut für Pharmakologie und Präventive Medizin
Observational
250
Bad Krozingen, Bad Nauheim, Bad Oeynhausen, Berlin, Bochum, Düsseldorf, Essen, Munich
2023-09-05
Active, closed
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 2
144
Berlin, Bochum, Münster, Ulm
2023-08-25
Recruiting
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
NCT06830421Primary Central Nervous System Lymphoma
University Hospital Freiburg
Phase 3
340
Freiburg im Breisgau, Stuttgart, Aachen, Augsburg, Berlin, Bielefeld, Bochum, Braunschweig
2023-08-09
Active, closed
A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
NCT06015841Parkinson Disease, Parkinson Disease 6, Early-Onset
DrugTriamcinolone
AC Immune SA
Phase 2
150
Bochum, Kassel, Kiel
2023-07-24
Recruiting
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
DrugsPonatinib·Imatinib·Blinatumomab
Goethe University
Phase 2
220
Aachen, Aschaffenburg, Augsburg, Bad Saarow, Bayreuth, Berlin, Bielefeld, Bochum
2023-07-14
Recruiting
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT05890677Lymphedema, Breast Cancer
University Hospital, Basel, Switzerland
Not applicable
280
Bochum, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Ludwigshafen am Rhein, Nuremberg
2023-07-14
Active, closed
Clinical Study to Evaluate Clinical Outcomes of LuxSmart IOL as Compared With LuxGood IOL
NCT06105190Cataract, Lens Opacities
Cutting Edge SAS
Not applicable
251
Ahaus, Bochum
2023-06-21
Recruiting
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
NCT05259605Glioma, Glioneuronal Tumor, Choroid Plexus Tumor, Pineal Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,650
Bochum, Bonn, Cologne, Essen, Frankfurt, Jena, Leipzig, Regensburg
2023-03-21
Active, closed
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05798156Lymphoma, Large B-Cell, Diffuse
DrugsPolatuzumab Vedotin·Glofitamab·Obinutuzumab·Rituximab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
125
Magdeburg, Berlin, Bochum, Chemnitz, Düsseldorf, Erlangen, Essen, Halle
2023-03-20
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Vico Therapeutics B. V.
Phase 1/2
68
Bochum, Bonn, Essen, Tübingen
2023-02-14
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Aachen, Berlin, Bochum, Bonn, Erlangen, Lübeck, Taufkirchen, Ulm
2023-02-03
Recruiting
GMMG Multiple Myeloma Registry
NCT07111884Multiple Myeloma
Prof. Dr. Hartmut Goldschmidt
Observational
999
Berlin, Bielefeld, Bochum, Bonn, Chemnitz, Cologne, Darmstadt, Düsseldorf
2022-12-08
Active, closed
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT05600777Cough, Refractory Chronic Cough
DrugCamlipixant
Bellus Health Inc. - a GSK company
Phase 3
997
Berlin, Bochum, Darmstadt, Dresden, Essen, Frankfurt, Frankfurt am Main, Geesthacht
2022-12-05
Active, closed
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
NCT05387525Keratosis, Actinic
DrugDiclofenac Sodium
Almirall, S.A.
Phase 4
447
Augsburg, Bad Bentheim, Bochum, Bonn, Detmold, Dresden, Erlangen, Hamburg
2022-10-24
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Berlin, Bochum, Halle, Hanover, Leipzig, Potsdam
2022-09-23
Recruiting
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04628026Acute Myeloid Leukemia
DrugVenetoclax
University of Ulm
Phase 3
650
Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt
2022-09-13
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05271409Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
DrugSatralizumab
Hoffmann-La Roche
Phase 3
132
Berlin, Bochum, Datteln, Düsseldorf, Mannheim, Munich
2022-08-30
Active, closed
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584Type 2 Diabetes
DrugTirzepatide
Eli Lilly and Company
Phase 4
780
Frankfurt am Main, Bochum, Essen, Saint Ingbert, Pirna, Oldenburg in Holstein, Bad Mergentheim, Gelnhausen
2022-08-01
Recruiting
Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases
NCT05124236Brain Metastases, Adult
Susanne Rogers
Not applicable
200
Bochum, Giessen, Kiel
2022-07-29
Active, closed
STAR-LIFE: a Post-market Registry on MINIject
NCT05269680Open Angle Glaucoma
iSTAR Medical
Observational
320
Bochum, Düsseldorf, Hamburg, Kiel, Lübeck, Ulm
2022-07-20
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
452
Aachen, Bochum
2022-07-14
Recruiting
CytOSorb TreatMent Of Critically Ill PatientS Registry
NCT05146336Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
CytoSorbents, Inc
Observational
3,000
Aachen, Bad Oeynhausen, Bochum, Essen, Göttingen, Herford, Jena, Kassel
2022-06-22
Active, closed
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254Metastatic Melanoma, Unresectable Melanoma
DrugsIO102-IO103·Pembrolizumab
IO Biotech
Phase 3
407
Augsburg, Berlin, Bochum, Erlangen, Essen, Frankfurt, Halle, Hamburg
2022-05-17
Active, closed
LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment
NCT04999423Intracranial Aneurysm
Microvention-Terumo, Inc.
Observational
206
Augsburg, Bochum, Essen, Münster
2022-01-14
Active, closed
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
NCT05139602Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 2
210
Erlangen, Berlin, Bochum, Dessau, Hamburg
2021-12-28
Recruiting
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
NCT05008809Colorectal Cancer
DrugsMFOLFOXIRI·MFOLFOX6·Folfiri·Folfox
Dominik Paul Modest
Phase 3
507
Amberg, Bad Saarow, Bayreuth, Berlin, Bochum, Bonn, Bremen, Chemnitz
2021-12-06
Recruiting
ITP Registry and Accompanying Biospecimen Collection
NCT05152238Immune Thrombocytopenia
Jena University Hospital
Observational
1,100
Aachen, Altenburg, Aschaffenburg, Bad Homburg, Bad Liebenwerda, Berlin, Biberach, Bochum
2021-11-29
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223Metastatic Colorectal Cancer
DrugsDivarasib·Tiragolumab·Inavolisib·Folfiri
Hoffmann-La Roche
Phase 1
542
Berlin, Bochum, Dresden, Düsseldorf, Hamburg, Heilbronn, München, Ulm
2021-10-22
Active, closed
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT04926818Multiple Sclerosis (MS)
DrugsSiponimod·Fingolimod·Ofatumumab
Novartis Pharmaceuticals
Phase 3
129
Freiburg im Breisgau, Göttingen, Bochum
2021-10-05
Active, closed
Plasma On Chronic Wounds for Epidermal Regeneration
NCT05855499Chronic Ulcer of Lower Extremity
Coldplasmatech
Not applicable
120
Tübingen, München, Regensburg, Hamburg, Bochum, Dresden, Berlin, Saalfeld
2021-10-01
Recruiting
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
NCT04844866Diffuse Large B-cell Lymphoma
Miltenyi Biomedicine GmbH
Phase 2
213
Augsburg, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig
2021-08-18
Active, closed
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709Muscle Invasive Bladder Cancer
DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
712
Bielefeld, Bochum, Cologne, Düsseldorf, Giessen, Hanover, Herne, Magdeburg
2021-08-05
Recruiting
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
NCT04803994Hepatocellular Carcinoma
DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3
434
Aachen, Amberg, Berlin, Bochum, Cologne, Dresden, Düsseldorf, Erlangen
2021-07-06
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsAdagrasib·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Amberg, Berlin, Bochum, Dresden, Frankfurt am Main, Hamburg, Herne, Mönchengladbach
2021-06-24
Recruiting
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).
NCT05331521Oligodendroglioma
DrugProcarbazine
University Hospital Heidelberg
Phase 3
406
Heidelberg, Berlin, Bochum, Bonn, Chemnitz, Cologne, Düsseldorf, Frankfurt
2021-04-07
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,205
Berlin, Bochum, Bonn, Frankfurt, Hanover, Leipzig, Lübeck, Magdeburg
2021-04-01
Recruiting
BoStOn SCientific Rhythm MAnagemenT REgiStry
NCT04823663Cardiac Disease
Boston Scientific Corporation
Observational
12,500
Berlin, Bochum
2021-03-31
Active, closed
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III
DrugAutogene cevumeran
BioNTech SE
Phase 2
327
Berlin, Bochum, Bonn, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg
2021-03-08
Active, closed
Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST
NCT04101851Breast Cancer Female, Breast Cancer
Toralf Reimer, MD PhD
Not applicable
350
Augsburg, Baden-Baden, Berlin, Bochum, Borna, Bottrop, Böblingen, Cottbus
2021-01-13
Active, closed
International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach
NCT04572230Intracranial Aneurysm
Stryker Neurovascular
Observational
405
Augsburg, Bochum
2020-12-21
Active, closed
WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia
NCT04801381BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
University of Bonn
Not applicable
202
Freiburg im Breisgau, Bochum, Bonn
2020-12-16
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
864
Berlin, Bochum, Dresden, Kiel, Leipzig, Ulm, Wiesbaden
2020-11-26
Active, closed
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
NCT04658199Progressive Supranuclear Palsy
UCB Biopharma SRL
Phase 1
19
Bochum, Düsseldorf, Essen, Hanover
2020-11-16
Active, closed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
DrugEfgartigimod PH20
argenx
Phase 2
229
Bochum, Cologne, Essen, Göttingen, Kiel, Potsdam
2020-09-18
Active, closed
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04468984Myelofibrosis (MF)
DrugsNavitoclax·Ruxolitinib
AbbVie
Phase 3
330
Mannheim, Mutlangen, Augsburg, Rostock, Bochum, Chemnitz, Dresden, Hamburg
2020-08-31
Active, closed
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
NCT04309409Malignant Melanoma Stage II
DrugsOpdivo·Nivolumab
University Hospital, Essen
Phase 3
374
Würzburg, Rostock, Augsburg, Bochum, Dortmund, Dresden, Erfurt, Essen
2020-07-01
Recruiting
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
NCT03993262Autoimmune Encephalitis
DrugBortezomib
Jena University Hospital
Phase 2
50
München, Würzburg, Jena, Hanover, Berlin, Bochum, Düsseldorf, Erlangen
2020-05-13
Active, closed
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
DrugsMidostaurin·Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
777
Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt
2019-12-20
Active, closed
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
NCT03474744Marginal Zone Lymphoma
DrugsCopanlisib Hydrochloride·Truxima·Rituximab
Christian Buske
Phase 2
36
Bochum, Bonn, Dingolfing, Goch, Goslar, Halle, Kassel, Landshut
2019-12-15
Active, closed
SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.
NCT04053088Cardiovascular Diseases
Institut für Pharmakologie und Präventive Medizin
Observational
500
Nuremberg, Passau, Würzburg, Frankfurt am Main, Oldenburg, Aachen, Bad Rothenfelde, Bochum
2019-12-12
Active, closed
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877Multiple Sclerosis, Relapsing-Remitting
DrugsPlegridy·Avonex
Biogen
Phase 3
152
Freiburg im Breisgau, Göttingen, Bochum, Berlin
2019-10-18
Active, closed
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
NCT03897127Acute Myeloid Leukemia
DrugsVyxeos·Daunorubicin·Cytarabine
University of Ulm
Phase 3
882
Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt
2019-09-04
Active, closed
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004Cutaneous Squamous Cell Carcinoma
DrugCemiplimab
Regeneron Pharmaceuticals
Phase 3
415
Heidelberg, Mainz, Berlin, Bochum, Buxtehude, Cologne, Dresden, Essen
2019-06-04
Active, closed
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
DrugsEnasidenib·Ivosidenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
968
Bad Saarow, Berlin, Bochum, Bonn, Braunschweig, Bremen, Dortmund, Düsseldorf
2019-03-01
Active, closed
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03827798Hidradenitis Suppurativa
DrugsArumakimig·Ianalumab·Remibrutinib
Novartis Pharmaceuticals
Phase 2
248
Bochum, Frankfurt, Hamburg, Schwerin
2019-02-27
Active, closed
Obinutuzumab in Marginal Zone Lymphoma
NCT03322865Marginal Zone Lymphoma
DrugObinutuzumab
Christian Buske
Phase 2
56
Bochum, Essen, Freiburg im Breisgau, Göttingen, Halle, Koblenz, Mainz, Mannheim
2018-11-23
Active, closed
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731Multiple Myeloma
DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide
University of Heidelberg Medical Center
Phase 3
662
Aachen, Bad Saarow, Berlin, Bielefeld, Bochum, Bonn, Braunschweig, Chemnitz
2018-10-18
Active, closed
Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
NCT03395587Glioblastoma
Heinrich-Heine University, Duesseldorf
Phase 2
136
Bochum, Duisburg, Düsseldorf, Lünen, Münster, Krefeld
2018-03-06
Recruiting
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis
NCT03334006Peritonitis, Sepsis, Septic Shock
RWTH Aachen University
Phase 2
200
Tübingen, Regensburg, Essen, Berlin, Aachen, Bochum, Dortmund, Dresden
2017-11-20
Active, closed
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
DrugsLederfolin·Leucovorin Calcium·Tecentriq·Fluorouracil
National Cancer Institute (NCI)
Phase 3
712
Dresden, Berlin, Bochum, Cologne, Esslingen am Neckar, Hamburg, Leipzig, Mannheim
2017-10-16
Recruiting
Registry for Patients With X-Linked Hypophosphatemia
NCT03193476X-Linked Hypophosphatemia
Kyowa Kirin Pharmaceutical Development Ltd
Observational
1,489
Bad Belzig, Bochum, Cologne, Dortmund, Freiburg im Breisgau, Hanover, Leipzig, Mainz
2017-09-12
Recruiting
MED-EL HEARING SOLUTIONS (MEHS): AN OBSERVATIONAL STUDY
NCT05668338Hearing Loss
MED-EL Elektromedizinische Geräte GesmbH
Observational
100
Bochum, Dresden, Frankfurt, Heidelberg, München, Oldenburg, Rostock, Tübingen
2017-06-26
Recruiting
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476Huntington's Disease
University College, London
Observational
2,500
Ulm, Dresden, Bochum, Erlangen, Münster, Taufkirchen
2017-01-01
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Augsburg, Berlin, Bochum, Erfurt, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2016-12
Recruiting
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
NCT02823821End-Stage Kidney Disease
University of Sydney
Phase 4
50,000
Albstadt, Berlin, Bochum, Darmstadt, Elsenfeld, Hechingen, Homburg, Langen
2016-06
Active, closed
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
NCT02726386Parkinson's Disease
NeuroDerm Ltd.
Phase 2
214
Beelitz-Heilstätten, Bochum, Bremerhaven, Dresden, Haag in Oberbayern, Ulm
2016-05-04
Recruiting
Registry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.
NCT05852418Amyotrophic Lateral Sclerosis
Ambulanzpartner Soziotechnologie APST GmbH
Observational
25,000
Berlin, Bochum, Bonn, Dresden, Essen, Göttingen, Hanover, Heidelberg
2015-10-30
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bad Reichenhall, Würzburg, Bochum, Düsseldorf, Dresden, Berlin, Cologne, Giessen
2015-01-20
Active, closed
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722Multiple Sclerosis
DrugsAvonex·Fingolimod
Novartis Pharmaceuticals
Phase 3
240
Freiburg im Breisgau, Göttingen, Dresden, Bochum, Erlangen
2013-07-26
Recruiting
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
NCT01574053Huntington's Disease
CHDI Foundation, Inc.
Observational
35,000
Aachen, Berlin, Bochum, Dresden, Erlangen, Freiburg im Breisgau, Kassel, Lübeck
2012-07
Active, closed
Longterm-Evaluation of Vitelene® Against Standard
NCT01713062Osteoarthritis, Hip, Arthritis
Aesculap AG
Observational
400
Bendorf, Bochum, Halle, Hanover, Mülheim, Olsberg
2012-01
Recruiting
Product Surveillance Registry
NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
Medtronic
Observational
100,000
Aachen, Arnsberg, Bad Oeynhausen, Berlin, Bielefeld, Bochum, Bremen, Cologne
2012-01
Recruiting
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
NCT01252485Acute Myeloid Leukemia (AML), MDS/AML
University of Ulm
Observational
50,000
Aschaffenburg, Augsburg, Aurich, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig
2010-07-06
Recruiting
The EUROSCA Natural History Study
NCT02440763Spinocerebellar Ataxia
Ataxia Study Group
Observational
400
Bochum, Bonn, Essen, Frankfurt, Tübingen
2005-07
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Berlin, Bochum, Bonn, Freiburg im Breisgau, Giessen, Halle, Hamburg, Mainz
2004-09-15
Rows per page Showing 1–203 of 203
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 October 2026. https://priyalifescience.com/clinical-trials-germany/city/bochum

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,042 studies in total at the last sync on 02 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 203 of those studies with a site in Bochum.

How many clinical trials are recruiting in Bochum?

116 of the 203 studies on this page are recruiting new participants as of the 02 Oct 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 78 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bochum), 203 studies
PhaseStudiesRecruitingShare
Phase 3904744.3%
Observational383218.7%
Phase 2351517.2%
Not applicable1788.4%
Phase 4843.9%
Phase 1/2643%
Phase 2/3532.5%
Phase 1432%

Most active sponsors

Lead sponsors with the most studies (Bochum)
Lead sponsorStudiesRecruiting
AstraZeneca1612
Novartis Pharmaceuticals112
Hoffmann-La Roche83
Novo Nordisk A/S74
argenx64
Eli Lilly and Company64
Sanofi62
Stichting Hemato-Oncologie voor Volwassenen Nederland53
AbbVie41
Boehringer Ingelheim44
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.